Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy

Part of paid clinical trials in Oklahoma City, Oklahoma.

Sponsor
University of Oklahoma
Study ID
NCT00222443
Phase
PHASE1
Status
Completed

Conditions

  • Lymphomas
  • Tumors

Eligibility Criteria

Sex
ALL
Age
1 Year - 21 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles of this chemotherapy and to estimate the response rate to this combination in children and adolescents with recurrent solid tumors and lymphomas.

Key Dates

Start date
Sep 30, 2004
Status verified
Sep 2008
Primary completion
Dec 31, 2007
Completion
Dec 31, 2007

Study Design

Enrollment
40 participants
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Primary Outcome Measure

Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan.

Locations (1)

FacilityCityStateZIPSite coordinators
Oklahoma University Health Sciences Center-Jimmy Everest CenterOklahoma CityOklahoma73104-

Find similar trials in Oklahoma City, OK

By research site
Oklahoma University Health Sciences Center-Jimmy Everest Center· Oklahoma City, OK

Related Studies